<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="16722">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02016209</url>
  </required_header>
  <id_info>
    <org_study_id>ZYTOP1402</org_study_id>
    <nct_id>NCT02016209</nct_id>
  </id_info>
  <brief_title>Neoadjuvant Chemotherapy of Nanoparticle Albumin-bound Paclitaxel in Lung Cancer</brief_title>
  <official_title>Phase II Study of Neoadjuvant Chemotherapy of Nanoparticle Albumin-bound Paclitaxel Plus Carboplatin/Cisplatin in Stage Ⅱ B and IIIA Non-small Cell Lung Cancer Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zhejiang University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Zhejiang University</source>
  <oversight_info>
    <authority>China: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      platinum-based albumin-bound paclitaxel regimen in advanced non-small cell lung cancer
      (NSCLC) especially in lung squamous cell carcinoma has a better tumor response rate and
      safety than solvent-based paclitaxel.However, the safety and efficacy is uncertain in
      neoadjuvant therapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The main purpose of this study is to observe the safety and efficacy of platinum-based
      albumin-bound paclitaxel regimen in the treatment of non-small cell lung cancer (NSCLC) of
      stage Ⅱ B and IIIA .
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>January 2014</start_date>
  <completion_date type="Anticipated">March 2016</completion_date>
  <primary_completion_date type="Anticipated">December 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Tumor response rate and Number of Adverse Events</measure>
    <time_frame>From date of randomization until the date of progression, assessed up to 2 months</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>disease free survival</measure>
    <time_frame>From date of surgery until the date of first documented progression, assessed up to 36 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <other_outcome>
    <measure>dynamic circulating tumor cell changes during treatment</measure>
    <time_frame>baseline, 3 weeks and up to progression disease</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Non Small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>nanoparticle albumin-bound paclitaxel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Neoadjuvant chemotherapy of platinum-based nanoparticle albumin-bound paclitaxel in stage Ⅱ B and IIIA non-small cell lung cancer</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>nanoparticle albumin-bound paclitaxel</intervention_name>
    <description>Neoadjuvant chemotherapy of nanoparticle albumin-bound paclitaxel in stage Ⅱ B and IIIA non-small cell lung cancer</description>
    <arm_group_label>nanoparticle albumin-bound paclitaxel</arm_group_label>
    <other_name>nab-paclitaxel</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        1.Histological or cytological diagnosis of NSCLC of Stage Ⅱ B and IIIA .

        2.18 years or older 3.Performance Status 0 to 2; 4.Appraisable disease; 5.patients can
        tolerant chemotherapy; 6.Total bilirubin 1.5 x upper limit of normal (ULN); 7.Creatinine
        clearance 60ml/min (calculated according to Cockcroft-gault formula).

        Exclusion Criteria:

        1.Any systemic anticancer treatment for NSCLC；2.Local radiotherapy for NSCLC；3.In this
        study within five years prior to the start of treatment with other than NSCLC patients
        with other cancers.4.Any instability in systemic disease; 5.Allergic to paclitaxel or
        Platinum;6.Pregnant or lactating women;7.Other researchers believe that does not fit into
        the group
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Qiong Zhao, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The first affiliated hospital, Zhejiang University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Qiong Zhao, PhD</last_name>
    <phone>0571-87236802</phone>
    <email>doczq.2008@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>The first affiliated hospital, Zhejiang University</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310003</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Qiong Zhao, PhD</last_name>
      <phone>0571-87236802</phone>
      <email>doczq.2008@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Qiong Zhao, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>December 2013</verification_date>
  <lastchanged_date>December 14, 2013</lastchanged_date>
  <firstreceived_date>December 7, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Zhejiang University</investigator_affiliation>
    <investigator_full_name>Qiong Zhao</investigator_full_name>
    <investigator_title>Chief of Department of Thoracic Oncology</investigator_title>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
    <mesh_term>Lung Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Paclitaxel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
